In vitro antitumor activity and targeted sites of two novel platinum-based(II) complexes on SW620 colon cancer cell line

Objective:The aim of our study was to evaluate the in vitro antitumor activity of two novel platinum-based(II) complexes(2.3-pyridinedicarboxylic acid dehydrate platinum and 2.3-pyrazinedicarboxylic acid dehydrate platinum),which were concurrently provided with hydrophilic carboxyl group and lipophilic pyrazinyl or pyridyl group,on SW620 colorectal cancer cell line and the impact of the two compounds on the cell cycle and apoptosis of the cells when compared with the oxaliplatin,desiring the new ligand combined with hydrophilic and lipophilic properties would facilitate the transportation and transmembrane of the drugs,showing a better antitumor activity.Methods:After SW620 cells were treated with different doses of the three platinum-based agents for 24,48 and 72 h,the cell proliferation inhibition rate was determined using methyl thiazolyl tetrazolium(MTT) assay;the morphology of cells were evaluated under inverted microscope;the changes in cell cycle were determined using flow cytometry;the percent apoptosis was measured using Annexin V/PI double staining and the micromorphology of the cells after drug exposure was evaluated using scanning electron microscopy.Results:The evaluation on the proliferation inhibition rate revealed that the three platinum-based agents inhibited the SW620 cells in a time-and dose-dependent manner and showed different strengths as pyridine > pyrazine > Oxa.Under optical microscope,the morphological changes such as cell shrinkage,round cells and dead cells were frequently observed after drug exposure.Cell cycle determination showed that all of the three agents could function to block the cells converting from phase S to phase G2M.Apoptosis evaluation revealed that the three agents promoted the apoptosis of SW620 cells in a time-and dose-dependent manner and showed different strengths as pyridine > pyrazine > Oxa.Typical early and late apoptotic morphological changes could be detected during electron microscopy.Conclusion:The two novel platinum-based(II) complexes showed a stronger antitumor effect on SW620 cells than oxaliplatin,with the targeted site at a certain phase of cell cycle and apoptosis.

Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer

BACKGROUND Type II diabetes mellitus(T2DM)has been associated with increased risk of colon cancer(CC)and worse prognosis in patients with metastases.The effects of T2DM on postoperative chemoresistance rate(CRR)and long-term disease-free survival(DFS)and overall survival(OS)in patients with stage III CC who receive curative resection remain controversial.AIM To investigate whether T2DM or glycemic control is associated with worse postoperative survival outcomes in stage III CC.METHODS This retrospective cohort study included 278 patients aged 40-75 years who underwent surgery for stage III CC from 2018 to 2021.Based on preoperative T2DM history,the patients were categorized into non-DM(n=160)and DM groups(n=118).The latter was further divided into well-controlled(n=73)and poorly controlled(n=45)groups depending on the status of glycemic control.DFS,OS,and CRR were compared between the groups and Cox regression analysis was used to identify risk factors.RESULTS Patients in the DM and non-DM groups demonstrated similar DFS,OS,and CRR(DFS:72.03%vs 78.75%,P=0.178;OS:81.36%vs 83.12%,P=0.638;CRR:14.41%vs 7.5%,P=0.063).Poorly controlled DM was associated with a significantly worse prognosis and higher CRR than well-controlled DM(DFS:62.22%vs 78.07%,P=0.021;OS:71.11%vs 87.67%,P=0.011;CRR:24.40%vs 8.22%,P=0.015).High preoperative fasting plasma glucose[DFS:Hazard ratio(HR)=2.684,P<0.001;OS:HR=2.105,P=0.019;CRR:HR=2.214,P=0.005]and glycosylated hemoglobin levels(DFS:HR=2.344,P=0.006;OS:HR=2.119,P=0.021;CRR:HR=2.449,P=0.009)indicated significantly poor prognosis and high CRR,while T2DM history did not(DFS:HR=1.178,P=0.327;OS:HR=0.933,P=0.739;CRR:HR=0.997,P=0.581).CONCLUSION Increased preoperative fasting plasma glucose and glycosylated hemoglobin levels,but not T2DM history,were identified as risk factors associated with poor postoperative outcomes and high CRR in patients with stage III CC.

融合NSGA-II和CSA的多目标车间调度

针对在灵活车间系统中调度作业和自动引导车(automated guide vehicle,AGV)的同时调度问题,考虑在有限多个AGV和加工机台的情况下,以最小化最大完工时间、单个AGV搬运消耗时间及所有AGV搬运总消耗时间为目标函数,设计融合NSGA-II(non-dominated sorting genetic algorithms)和克隆选择(clonal selection algorithm,CSA)的改进算法INGCSA来解决此类问题。采用工件、加工机台和AGV三部分编码;引入非支配排序和目标函数值大小排序后总得分进行种群分层,从而有效地保留优秀个体;针对克隆后的种群,对不同等级的种群采取不同的变异概率,并对染色体进行内部交换与均匀交叉混合交换的基因重组,有效地提高了种群的多样性与防止陷入局部最优。通过三组对比实验,验证了该算法在探索最优解时,具有运行时间短、稳定性高和收敛性好等优点。

基于区间毕达哥拉斯犹豫模糊熵和交叉熵的ELECTRE II决策方法

针对属性权重完全未知或部分已知,属性值为区间毕达哥拉斯犹豫模糊数的多属性决策问题,提出了基于区间毕达哥拉斯犹豫模糊熵和交叉熵的ELECTRE II法。首先给出区间毕达哥拉斯犹豫模糊数的区间形式的得分函数和精度函数,定义新的距离测度。然后基于区间毕达哥拉斯犹豫模糊数的模糊因子、直觉因子和幅度因子,给出熵和交叉熵公式,并证明其性质,提出了基于熵和交叉熵确定属性权重的方法。最后提出了区间毕达哥拉斯犹豫模糊环境下的改进的ELECTRE II法,利用综合优势值对方案进行排序,并通过算例和比较分析验证了该方法的可行性和有效性。

基于改进NSGA-II的轨道交通接驳公交线路优化

为解决接驳公交线路规划不合理和时间安排不完善的问题,提出了基于改进NSGA-II算法的环形接驳公交线路优化方法。首先,结合双层规划理论,以乘客出行时间成本最小化、公交企业运营收益和接驳公交服务率最大化为目标函数,以接驳公交线路站点数、线路长度和发车频率作为约束条件构建上层模型,采用Logit模型构建了下层接驳客流分配模型;其次,运用Floyd算法对NSGA-II算法的初始化种群进行了优化,针对所提出的模型设计了模型求解流程;最后,以哈尔滨市轨道交通1号线医大一院轨道交通站为案例,运用笔者提出的多目标双层规划模型和算法进行求解,并与原NSGA-II算法和基于Logistic混沌映射的NSGA-II算法进行对比。研究结果表明:基于Floyd算法改进的NSGA-II算法在多目标双层规划模型求解时,收敛速度更快效果更好,求解结果可以在Pareto前沿得到多个相互非支配的最优解;不同解集对应目标函数值不同,但可以达到接驳公交网络整体效益最优,采用折衷最优解集表述求解结果。

渤海湾沿海低地第II海相层MIS5a阶段海侵与全球海平面变化的时间对比研究

【研究目的 】渤海湾地区第II海相层的形成时代仍存争议,制约着该地区海平面变化研究进展。本研究对该层进行光释光定年,以期标定准确的地层年代及对应的海侵期次。【研究方法 】以渤海湾西岸CZ80、CZ85、CZ66钻孔为研究对象,在岩心沉积结构、构造及有孔虫丰度,沉积微相研究基础上,识别出了第II海相层,并建立了第II海相层对比剖面。通过光释光测年方法对该地层的形成时代进行了准确测定,进一步讨论第II海相层的发育时间与全球海平面变化关系。【研究结果 】CZ80、CZ85及CZ66孔在全新统(含第I海相层)以下均钻遇到了第II海相层,海相层底板埋深在35~33m,对应黄海高程-31.13~-28.39m,顶板埋深32~20m,高程-25.58~-15.39 m。光释光测年结果表明第II海相层所对应的海侵事件发育时间约为94~71 ka。【结论 】光释光测年结果表明,该区第II海相层始于94 ka或更早,海水影响在距今约71 ka结束。对比全球海面曲线,第II海相层时空特征与MIS5a阶段相符,记录了MIS5a阶段海侵事件。

A radiomics prognostic scoring system for predicting progression-free survival in patients with stageⅣnon-small cell lung cancer treated with platinum-based chemotherapy

Objective:To develop and validate a radiomics prognostic scoring system(RPSS)for prediction of progressionfree survival(PFS)in patients with stageⅣnon-small cell lung cancer(NSCLC)treated with platinum-based chemotherapy.Methods:In this retrospective study,four independent cohorts of stageⅣNSCLC patients treated with platinum-based chemotherapy were included for model construction and validation(Discovery:n=159;Internal validation:n=156;External validation:n=81,Mutation validation:n=64).First,a total of 1,182 three-dimensional radiomics features were extracted from pre-treatment computed tomography(CT)images of each patient.Then,a radiomics signature was constructed using the least absolute shrinkage and selection operator method(LASSO)penalized Cox regression analysis.Finally,an individualized prognostic scoring system incorporating radiomics signature and clinicopathologic risk factors was proposed for PFS prediction.Results:The established radiomics signature consisting of 16 features showed good discrimination for classifying patients with high-risk and low-risk progression to chemotherapy in all cohorts(All P<0.05).On the multivariable analysis,independent factors for PFS were radiomics signature,performance status(PS),and N stage,which were all selected into construction of RPSS.The RPSS showed significant prognostic performance for predicting PFS in discovery[C-index:0.772,95%confidence interval(95%CI):0.765-0.779],internal validation(C-index:0.738,95%CI:0.730-0.746),external validation(C-index:0.750,95%CI:0.734-0.765),and mutation validation(Cindex:0.739,95%CI:0.720-0.758).Decision curve analysis revealed that RPSS significantly outperformed the clinicopathologic-based model in terms of clinical usefulness(All P<0.05).Conclusions:This study established a radiomics prognostic scoring system as RPSS that can be conveniently used to achieve individualized prediction of PFS probability for stageⅣNSCLC patients treated with platinumbased chemotherapy,which holds promise for guiding personalized pre-therapy of stageⅣNSCLC.

Associations of genetic polymorphisms of the transporters organic cation transporter 2(OCT2),multidrug and toxin extrusion 1(MATE1),and ATP-binding cassette subfamily C member 2(ABCC2) with platinum-based chemotherapy response and toxicity in non-small cel

Background:Platinum-based chemotherapy is the first-line treatment of non-small cell lung cancer(NSCLC);it is therefore important to discover biomarkers that can be used to predict the efficacy and toxicity of this treatment.Four important transporter genes are expressed in the kidney,including organic cation transporter 2(OCT2),multidrug and toxin extrusion 1(MATEl),ATP-binding cassette subfamily B member 1 {ABCB1),and ATP-binding cassette subfamily C member 2(ABCC2),and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs.This study aimed to evaluate the association of genetic polymorphisms of these transporters with platinumbased chemotherapy response and toxicity in NSCLC patients.Methods:A total of 403 Chinese NSCLC patients were recruited for this study.All patients were newly diagnosed with NSCLC and received at least two cycles of platinum-based chemotherapy.The tumor response and toxicity were evaluated after two cycles of treatment,and the patients' genomic DNA was extracted.Seven single-nucleotide polymorphisms in four transporter genes were selected to investigate their associations with platinum-based chemotherapy toxicity and response.Results:OCT2 rs316019 was associated with hepatotoxicity(P = 0.026) and hematological toxicity(P = 0.039),and MATEl rs2289669 was associated with hematological toxicity induced by platinum(P = 0.016).In addition,ABCC2rs717620 was significantly associated with the platinum-based chemotherapy response(P = 0.031).ABCB1 polymorphisms were associated with neither response nor toxicity.Conclusion:OCT2 rs316019,MATEl rs2289669,and ABCC2 rs717620 might be potential clinical markers for predicting chemotherapy toxicity and response induced by platinum-based treatment in NSCLC patients.Trial registration Chinese Clinical Trial Registry

营心宁胶囊辅助治疗对冠心病心力衰竭患者血管紧张肽II水平和心功能的影响

目的:观察营心宁胶囊辅助治疗对冠心病心力衰竭患者血管紧张肽II (AngII)水平和心功能的影响。方法:将128例患者分为两组,对照组64例,治疗组64例。对照组予常规治疗,治疗组患者在此基础上加用营心宁胶囊治疗,每次4粒,每日3次。治疗前及治疗8周后检测血浆AngII、脑钠肽(BNP),并行心脏彩色多普勒超声心动图测定左室射血分数(LVEF)、左室舒张末期内径(LVEDD)和每搏输出量(SV)。结果:治疗组和对照组总有效率分别为92.2%和89.1% (P > 0.01);显效率分别为43.8%,32.8% (P < 0.01)。两组治疗后患者的AngII、BNP、LVEF、LVEDD和SV均较治疗前明显改善(P < 0.01或P < 0.05),且治疗组患者的改善水平优于对照组(P < 0.01)。结论:营心宁胶囊能有效降低患者AngII水平,并对心功能有改善作用。

血管紧张素II对脓毒症休克大鼠心脏功能的影响

本研究拟通过盲肠结扎穿孔制备大鼠脓毒症模型,观察血管紧张素II对脓毒症休克(sepsis-shock)大鼠心脏功能的影响。方法 48只(Sprague-Dawley,SD)雄性大鼠随机分为6组(n=8):对照(control)组、假手术(sham)组、脓毒症休克(SS)组、去甲肾上腺素(NE)治疗组、血管紧张素II (ANGII)治疗组。采用盲肠结扎穿孔制备脓毒症休克动物模型。监测大鼠心率、血压变化。监测过程中大鼠如出现平均动脉压下降至65mmHg以下,立即给予0.9%生理盐水进行液体复苏,观察10分钟后如效果不佳,按照分组给予不同血管活性药物泵入。分别在造模后6,12,18,24小时抽血行心肌酶学指标检测,同时在该时段行超声观察大鼠心脏超声检查。于术后24小时留取心脏组织进行氧化因子指标测定,并进行心脏组织病理学观察。结果 与对照组和假手术组对比,脓毒症休克、去甲肾上腺素组、血管紧张素组平均动脉压下降明显,液体复苏效果欠佳,需要血管活性药物干预。与对照组和假手术组对比,脓毒症休克、去甲肾上腺素组、血管紧张素II组炎症反应、乳酸指标明显升高,具有统计学差异(P<0.05)。脓毒症休克组与对照组、假手术组相比,心脏左室射血分数(LVEF)明显下降,具有统计学差异(P<0.05),应用血管活性药物后,左室射血分数明显提高,血管紧张素II组射血分数提高与脓毒症组相比,具有显著统计学差异(P<0.01)。脓毒症休克组与对照组、假手术组相比,心肌酶学指标明显升高,应用去甲肾上腺素或血管紧张素II干预后,心肌酶学指标下降,与脓毒症组相比,具有统计学差异(P<0.05),血管紧张素II组改善更为明显(P<0.01)。结论 血管紧张素II可改善脓毒症休克对大鼠的心肌损害,对脓毒症休克大鼠心肌有一定的保护作用。

表达Strep-tag II的重组塞内卡病毒的构建与鉴定

为构建表达Strep-tag II的重组塞内卡病毒(SVA),本研究在感染性cDNA克隆p SVA-I212V/S460L的基础上,采用重叠延伸PCR扩增Strep-tag II并采用无缝克隆法将其插入SVA VP1基因C端,构建感染性cDNA克隆,命名为p SVA-Strep,并采用双酶切和测序鉴定正确后,将p SVA-Strep转染BHK-21细胞拯救重组病毒,收集病变细胞上清,并将含有病毒的细胞上清和野生型SVA(SVA-WT)分别感染BHK-21细胞,以未感染病毒的BHK-21细胞作为阴性对照,感染后24 h分别以鼠源SVA VP2蛋白单克隆抗体(MAb)5D10(1∶1000)、鼠源Strep-tag II MAb(1∶2000)作为一抗,以FITC标记的山羊抗小鼠Ig G(1∶2000)为二抗,采用间接免疫荧光试验(IFA)对重组病毒鉴定。IFA结果显示,以鼠源SVA VP2蛋白MAb 5D10为一抗,SVA-WT和重组病毒感染的细胞均出现绿色荧光,以Strep-tag II MAb作为一抗时,仅有重组病毒感染的细胞出现绿色荧光,经SVA-WT感染的BHK-21细胞及阴性对照细胞均无绿色荧光,表明拯救了Strep-tag II标记的重组病毒,并将其命名为r SVA-Strep。将r SVA-Strep在BHK-21细胞中连续传10代,每隔2代采用引物VP1-F/R经PCR鉴定并对第10代重组病毒的VP1基因测序以鉴定r SVA-Strep的遗传稳定性。结果显示,每隔两代的重组病毒经PCR扩增后均出现约780 bp的目的条带,第10代重组病毒扩增的VP1基因测序结果显示Strep-tag II基因仍在重组病毒中,且无基因突变,表明r SVA-Strep的遗传稳定性较强;将SVA-WT和r SVA-Strep分别以MOI 0.01感染BHK-21细胞,在感染后4 h、8 h、12 h、24 h、36 h、48 h和72 h收获病毒测定病毒滴度并绘制生长曲线,结果显示在病毒感染36 h内r SVA-Strep和SVA-WT生长动力学基本一致,表明Strep-tag II的引入在病毒感染36 h内对SVA的复制基本无影响。采用0.2%甲醛充分灭活r SVA-Strep,并利用Strep-TactinRXT Purification纯化试剂盒纯化该灭活病毒,将r SVA-Strep灭活病毒上清加至Strep-Tactin亲和层析柱,分别用不同体积洗脱缓冲液依次洗脱病毒并通过western blot鉴定病毒的纯化效果。对纯化过程中不同洗脱液洗脱病毒的western blot结果显示,不同体积的洗脱液中E1、E2和E3均出现VP0和VP2两条带,且E1和E2的条带最明显,表明洗脱缓冲液的最佳洗脱体积约为2.2 CV;以上结果表明r SVA-Strep可通过Strep-Tactin亲和层析柱一步法纯化。本研究在SVA中插入Strep-tag II标签,为SVA灭活疫苗的快速纯化提供技术手段,也为其他病原的快速纯化方法的建立提供参考。

基于NSGA-II遗传算法的定轴注射模具成型工艺参数优化

为解决注射成型过程中铸件的质量和铸造效率低等问题,提出一种NSGA-II算法和TOPSIS方法与响应面法相结合的新型注射工艺参数优化筛选方法。以定轴为研究对象,采用Box-Behnken设计,以熔体温度、模具温度、注射时间、保压压力为变量,以翘曲变形量和体积收缩率为响应变量,采用NSGA-II遗传算法对2个响应的目标函数执行优化,用TOPSIS方法求解优化得到的Pareto前沿解集,找到最优解。仿真结果表明,当注射时间为40.71s、模具温度为131℃、熔体温度为180.07℃、保压压力为65 MPa时,翘曲变形降低了10.92%、体积收缩率降低了11.19%。优化后的注射工艺参数可有效消除铸件内部收缩松动和缩孔缺陷,形成性能良好的致密铸件,提高了产品质量。

Weight Loss and Gastrointestinal Symptoms in Advanced Cancer Patients Treated with Platinum-based Chemotherapy

Objective This study assessed the weight loss changes and gastrointestinal symptoms in patients with advanced tumors receiving platinum-containing chemotherapy.Methods We retrospectively reviewed 297 patients with advanced cancers[124 gastrointestinal(GI)cancer patients,119 lung cancer patients and 54 head and neck cancer(HNC)patients]receiving first-line chemotherapy at Tongji Hospital.The patients’changes in body weight,body mass index(BMI),and biochemical parameters(serum haemoglobin and albumin levels)were compared before and after two chemotherapy cycles.Results More than half[54.88%(163/297)]of the patients had experienced unintentional weight loss in the 6 months before chemotherapy,and weight loss≥5%and≥10%of the body mass was noted in 35.69%and 20.20%of the patients,respectively.After two cycles of platinum-based chemotherapy,the proportions of patients with a>5%reduction in body weight among patients with GI,lung,and head and neck cancers were 47.5%(59/124),44.53%(53/119),and 46.2%(25/54),respectively.The patients with GI and lung cancers were more vulnerable to extreme weight loss(≥10%)than those with HNC(P=0.025).The serum hemoglobin levels were also remarkably decreased relative to those before chemotherapy(all P<0.05).Common GI symptoms reported by all patients included anorexia(61.28%),vomiting(52.53%),and nausea(51.18%).A higher proportion of patients with≥10%weight loss experienced anorexia and vomiting(OR=12.21 and 3.61,P=0.008 and 0.047,respectively).Conclusions For advanced cancer patients receiving platinum-based chemotherapy,the GI symptoms are the major factor related to their nutritional status.Appropriate nutritional screening,evaluation and treatment should be applied during the treatment of cancer in order to reduce GI symptoms and improve the patient’s nutritional status.

Platinum-based nanopharmaceuticals used to overcome cisplatin resistance in vitro and in vivo

Cisplatin resistance still remains a major obstacle to successful treatment of cancer.The development of cellular resistance to platinum-based chemotherapies is often associated with reduced intracellular platinum concentrations.In some models,this reduction is due to abnormal membrane protein trafficking,resulting in reduced uptake by transporters at the cell surface.Given the central role of platinum drugs in the clinic.

Fe(II)改性蒙脱石对土壤汞的吸附固定机理探究

为明确Fe-MMT对土壤汞离子(Hg^(2+))的吸附、解吸特性及潜在作用机理,采用FeSO_(4)·7H_(2)O改性钠基蒙脱土(Na-MMT),合成了Fe(II)基蒙脱石(Fe-MMT),并探究了不同pH值、吸附剂用量、Hg^(2+)初始浓度和反应时间等条件下,Fe-MMT对土壤Hg^(2+)的吸附解吸特性、吸附动力学和等温吸附模型。结果发现:在pH=5、吸附剂用量为0.5 g、Hg^(2+)初始浓度为170 mg/L、反应时间为0.5 h的条件下,Fe-MMT对土壤Hg^(2+)的去除率高达76.8%;Fe-MMT对Hg^(2+)+的吸附过程符合Langmuir等温吸附模型,伪二阶动力学模型可较好地拟合吸附动力学行为,表明该吸附过程主要为单分子层吸附,且主要发生在吸附剂表面的均相反应位点上;结合微观结构表征,发现Fe-MMT对土壤Hg^(2+)的吸附主要通过-S^(2-)、-SH和-OH与Hg^(2+)进行络合,以及Fe^(2+)与Hg^(2+)的原位共沉淀络合引起的;Fe-MMT在水-土混合体系中的解吸率为9.7%,表明Fe-MMT对土壤Hg^(2+)具有较强的固定作用。可见,Fe-MMT具有修复Hg污染土壤的潜力。

Determination of Residues and Safety Analysis of Metal Impurities in Platinum-based Antitumor Drugs

The residual metal impurities in cisplatin, carboplatin and oxaliplatin were determined by ICP-AES. The samples were ignited and dissolved with HCl:HNO 3 (3:1). The method is simple and accurate. By the determination of the metal residues in the samples, the calculated actual daily exposure and concentration of the metal Pd, Ir, Rh, Ru, Mo, Ni, Cr, V, Cu, Mn, Fe and Zn that were less than the permitted daily exposures (PDE) and the limited concentration permitted in the EMEA guideline on the specification limits for residues of metal catalysts or metal reagents [1] . The metal residues can de adequately removed from the active pharmaceutical ingredients and the corresponding drugs. The trace metal residues will not affect human health and lead to the safety hazard by the intravenous injection.

Research progress in the use of combinations of platinum-based chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors

In the past decade,the advent of the epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)has dramatically influenced the therapeutic strategies for treating lung cancer,but with tumor progression and drug resistance,patients will ultimately develop reduced sensitivity to EGFR-TKIs.How can we delay the emergence of drug resistance? What is the next strategy after drug resistance? How to reasonably combine platinum-based chemotherapy and EGFR-TKIs? These questions are currently the focus of lung cancer research.Clinical studies have reported that platinum-based chemotherapy can increase the sensitivity to EGFR-TKIs.However,results of pre-clinical and clinical studies have been inconsistent.The mechanisms of platinum chemotherapy and EGFR-TKIs are still unknown due to the lack of systematic research.Therefore,systematic studies are required to show the mechanisms of EGFR-TKIs and chemotherapy agents and define the markers sensitive to their combinations when given concurrently or sequentially.

成人低角型安氏II类1分类与安氏II类2分类错合畸形矫治前唇颏形态差异性研究

通过对比成人低角型安氏II类1分类和安氏II类2分类错合畸形患者的面部形态特点及唇颏形态,为临床制定矫治方案和临床治疗工作提供思路。方法 分别选取低角型安氏I类1分类和安氏II类2分类错合畸形患者40例,男女比例为1:1,年龄:18-25岁.通过将侧貌X线片和面部90°面相重合,对测量面部软组织21项指标进行测量。结果 上唇突点—E线距离,下唇突点—E线距离,上唇倾角,下唇倾角,上唇厚度,上下唇面积对比均有统计学意义(P<0.05)。结论 低角型安氏II类1分类与安氏II类2分类相比,上下唇均呈前突状,上唇面积,安氏II类1分类较安氏II类2分类小,下唇面积,安氏II类1分类较安氏II类2分类大。

Impacts of angiotensin II on retinal artery changes in apolipoprotein E deficient mice

AIM:To investigate the impacts of angiotensin II(Ang II)on retinal artery changes in apolipoprotein E deficient(apoE^(-/-))mice.METHODS:ApoE^(-/-)male mice were infused by minipumps with Ang II at 1000 ng/kg·min(Ang II group)or saline(control group)for 28d.They were underwent ophthalmic fundus examination on day 0,14,and 28 of infusion.Histopathologic examination,ribonucleic acid(RNA)sequencing and local Ang II measurement of retinas were conducted.RESULTS:Ophthalmic fundus examination showed Ang II infusion promoted the formation of retinal arterial aneurysm-like lesions on day 28.Optical coherence tomography revealed the ganglion cell and inner plexiform layer(GCIPL)thickness in the control group was significantly thinner than that in Ang II group(P<0.001).Hematoxylin-eosin staining demonstrated diffused swelling of GCIPL layer and its disordered structure in Ang II group.Transmission electron microscopy showed Ang II infusion caused aggravation of atherosclerotic lesions,including increased swelling,roughness,disorganization of the retinal vasculature,and vacuoles formation.RNA-sequencing and gene ontology enrichment analysis demonstrated that the structure and function of cellular membrane might be disturbed and visual function might be compromised by Ang II.The local level of Ang II was higher in Ang II infusion group but did not show significant differences compared to the control group(P=0.086).CONCLUSION:Ang II infusion promotes the formation of retinal arterial aneurysm-like lesions in apoE^(-/-)mice,causing aggravation of atherosclerotic lesions,more severe disorganization of the retinal vasculature and disturbance of the cellular membrane.

青霜露暴露治疗II度烧烫伤临床观察

目的:观察青霜露暴露治疗烧烫伤的临床效果。方法:门诊II度烧烫伤患者100例,其中浅II度67例,深II度33例。以暴露疗法在烧烫伤创面青霜露局部用药,每日1~3次,直至愈合。结果:67例浅II度烧烫伤创面经青霜露治疗全部愈合,愈合时间最短6天,最长30天;33例深II度烧烫伤创面经青霜露治疗30天痊愈31例,显效2例,愈合时间最短14天。所有创面愈合良好,局部疼痛消失和无明显增生性瘢痕。结论:青霜露治疗烧烫伤促进创面愈合,疗效确切;本方法简单方便,值得临床推广应用。